Serge Saxonov - 10X GENOMICS Chief Executive Officer, Co-Founder, Director
| 1KJ Stock | EUR 12.61 0.07 0.56% |
CEO
Serge Saxonov is Chief Executive Officer, Co-Founder, Director of 10X GENOMICS DL since 2012.
| Age | 42 |
| Tenure | 12 years |
| Phone | 925 401 7300 |
| Web | http://www.10xgenomics.com |
Serge Saxonov Latest Insider Activity
Tracking and analyzing the buying and selling activities of Serge Saxonov against 10X GENOMICS stock is an integral part of due diligence when investing in 10X GENOMICS. Serge Saxonov insider activity provides valuable insight into whether 10X GENOMICS is net buyers or sellers over its current business cycle. Note, 10X GENOMICS insiders must abide by specific rules, including filing SEC forms every time they buy or sell 10X GENOMICS'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Serge Saxonov over a month ago Disposition of 1850 shares by Serge Saxonov of 10X Genomics subject to Rule 16b-3 | ||
Serge Saxonov over a month ago Disposition of 534 shares by Serge Saxonov of 10X Genomics at 55.064 subject to Rule 16b-3 | ||
Serge Saxonov over three months ago Disposition of 1000 shares by Serge Saxonov of 10X Genomics at 49.5301 subject to Rule 16b-3 | ||
Serge Saxonov over six months ago Disposition of 4660 shares by Serge Saxonov of 10X Genomics at 43.9959 subject to Rule 16b-3 |
10X GENOMICS Management Efficiency
The company has return on total asset (ROA) of (0.0892) % which means that it has lost $0.0892 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2122) %, meaning that it generated substantial loss on money invested by shareholders. 10X GENOMICS's management efficiency ratios could be used to measure how well 10X GENOMICS manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 4 records | CEO Age | ||
| Jason Gorevic | Teladoc | 51 | |
| Jon Kessler | Healthequity | 55 | |
| Seth Blackley | Evolent Health | 44 | |
| Peter Gassner | Veeva Systems | 58 | |
Management Performance
| Return On Equity | -0.21 | |||
| Return On Asset | -0.0892 |
10X GENOMICS DL Leadership Team
Elected by the shareholders, the 10X GENOMICS's board of directors comprises two types of representatives: 10X GENOMICS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of 10X. The board's role is to monitor 10X GENOMICS's management team and ensure that shareholders' interests are well served. 10X GENOMICS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, 10X GENOMICS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mathai Mammen, Independent Director | ||
| Bradford Crutchfield, Chief Commercial Officer | ||
| Jean Philibert, Chief People Officer | ||
| Benjamin Hindson, President Co-Founder, Chief Scientific Officer, Director | ||
| Brad Crutchfield, Chief Commercial Officer | ||
| Justin McAnear, Chief Financial Officer | ||
| Shehnaaz Suliman, Independent Director | ||
| Eric Whitaker, General Counsel | ||
| Serge Saxonov, Chief Executive Officer, Co-Founder, Director | ||
| Sridhar Kosaraju, Independent Director | ||
| Bryan Roberts, Independent Director | ||
| John Stuelpnagel, Independent Chairman of the Board | ||
| Kimberly Popovits, Independent Director |
10X Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is 10X GENOMICS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | |||
| Return On Asset | -0.0892 | |||
| Profit Margin | (0.33) % | |||
| Operating Margin | (0.28) % | |||
| Shares Outstanding | 95.6 M | |||
| Shares Owned By Insiders | 2.60 % | |||
| Shares Owned By Institutions | 99.56 % | |||
| Revenue | 503.71 M | |||
| Gross Profit | 416.4 M | |||
| EBITDA | (117.15 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in 10X Stock
10X GENOMICS financial ratios help investors to determine whether 10X Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 10X with respect to the benefits of owning 10X GENOMICS security.